Immune checkpoint inhibition-related colitis: Symptoms, endoscopic features, histology and response to management

ESMO Open

Volumn 3, Issue 1, 2018, Pages

  Geukes Foppen, Marnix H ^a   Rozeman, Elisa A ^a   Van Wilpe, Sandra ^a   Postma, Cindy ^a   Snaebjornsson, Petur ^a   Van Thienen, Johannes V ^a   Van Leerdam, Monique E ^a   Van Den Heuvel, Michel ^a   Blank, Christian U ^a   Van Dieren, Jolanda ^a   Haanen, John B A G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

colitis; endoscopy; immunotherapy; infliximab

Indexed keywords

BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; IPILIMUMAB; MYCOPHENOLIC ACID; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; TACROLIMUS;

ADULT; AGED; CANCER IMMUNOTHERAPY; COHORT ANALYSIS; COLITIS; COLONOSCOPY; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PANCOLITIS; RECTUM HEMORRHAGE; RETROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 85046835830     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2017-000278     Document Type: Review

References (24)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-30.
3. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372:2521-32.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
5. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
6. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
7. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20.
8. Ibrahim RA, Berman DM, DePril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011;29(15 suppl):8583.
9. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013;119:1675-82.
10. Yervoy. Highlights of prescribing information, 2011. pp. 1-20. https://www.accessdata. fda.gov/drugsatfda_ docs/label/2011/125377s0000lbl.pdf. (accessed 30 May 2017).
11. Keytruda. Highlights of prescribing information, 2016. pp. 1-26. https://www.accessdata. fda.gov/drugsatfda_ docs/label/2016/125514s012lbl.pdf. (accessed 30 May 2017).
12. Opdivo. Highlights of prescribing information, 2014. pp. 1-20. https://www.accessdata. fda.gov/drugsatfda_ docs/label/2014/125554lbl.pdf. (accessed 30 May 2017).
13. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv119-42.
14. Lin R, Yellin MJ, Lowy I, et al. An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy. J Clin Oncol 2008;26(15 suppl):9063.
15. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
16. van der Heide H, van den Brandt-Gradel V, Tytgat GN, et al. Comparison of beclomethasone dipropionate and prednisolone 21-phosphate enemas in the treatment of ulcerative proctitis. J Clin Gastroenterol 1988;10:169-72.
17. Verschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. Clin Gastroenterol Hepatol 2016;14:836-42.
18. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase ii and iii trials. J Clin Oncol 2017;35:3807-14.
19. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
20. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11.
21. Panteris V, Haringsma J, Kuipers EJ, et al. mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy 2009;41:941-51.
22. Bellini D, Rengo M, De Cecco CN, et al. Perforation rate in CT colonography: a systematic review of the literature and metaanalysis. Eur Radiol 2014;24:1487-96.
23. Singh K, Narula AK, Thukral CL, et al. Role of ct colonography in colonic lesions and its correlation with conventional colonoscopic findings. J Clin Diagn Res 2015;9:TC14-18.
24. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.